

wherein the peptide is a cross-linked peptide with a cross-linker to connect a first amino acid Xaa₁ to a second amino acid Xaa₃, Xaa₁ is (R)-2-(4'-pentenyl)alanine, Xaa₃ is (R)-2-(4'-pentenyl)alanine; and Xaa₂ is S or P, Xaa₅ is F or Y.

5 [005b] In yet another aspect, the present invention provides a pharmaceutical composition comprising a peptide disclosed herein.

[005c] In yet another aspect, the present invention provides use of a peptide disclosed herein, in the manufacture of a medicament for treating or preventing cancer in a patient.

10 [006] Disclosed is a peptide comprising or consisting of the amino acid sequence of TSFXaa₁EYWXaa₃LLXaa₂, wherein Xaa₁ is (R)-2-(7'-octenyl)alanine or derivative thereof, or is (R)-2-(4'-pentenyl)alanine or derivative thereof; and Xaa₂ and Xaa₃ are independently any type of amino acid or modified amino acid. Also disclosed is a peptide comprising or consisting of the amino acid sequence of TSFXaa₁EYW Xaa₃LLXaa₂ENXaa₅, wherein Xaa₁ and Xaa₃ are any type of amino acid or modified amino acid; Xaa₂ is S, or P, or (S)-2-(4'-pentenyl)alanine or a derivative of (S)-2-(4'-pentenyl)alanine; and wherein Xaa₅ is F or Y. Also disclosed is

1. A peptide comprising or consisting of the amino acid sequence of:




wherein the peptide is a cross-linked peptide with a cross-linker to connect a first amino acid Xaa₁ to a second amino acid Xaa₂; Xaa₁ is (R)-2-(7'-octenyl)alanine, Xaa₂ is (S)-2-(4'-pentenyl)alanine, Xaa₃ is A, Xaa₅ is F or Y;


or

wherein the peptide is a cross-linked peptide with a cross-linker to connect a first amino acid Xaa₁ to a second amino acid Xaa₃, Xaa₁ is (R)-2-(4'-pentenyl)alanine, Xaa₃ is (R)-2-(4'-pentenyl)alanine; and Xaa₂ is S or P, Xaa₅ is F or Y.

2. The peptide of claim 1, wherein the peptide comprises the formula:



or:



wherein:

R₁ is -C(OH)CH₃ [T];

R₂ is -CH₂OH [S];

R₃ is benzyl [F];

R₄ is -CH₃ [(R)-2-(7'-octenyl)alanine or (R)-2-(4'-pentenyl)alanine];

R₅ is - (CH₂)₂C(O)OH [E];

R₆ is -CH₂-Phenyl-OH [Y];

R₇ is the side chain of Trp, wherein C₆ of Trp is substituted with a hydrogen or a halogen and/or wherein Trp is independently an L or D optical isomer;

R₈ is -CH₃ [A or (R)-2-(4'-pentenyl)alanine];

R₉ and R₁₀ are -CH₂CH(CH₃)₂ [L];

R₁₁ is -CH₂OH [S] or -(CH₂)₃- [P] or -CH₃ [(S)-2-(4'-pentenyl)alanine];

R is C₈ alkenyl or C₁₁ alkenyl

R₁₂ is – (CH₂)₂C(O)OH [E];

R₁₅ is –CH₂C(O)NH₂ [N];

R₁₆ is benzyl [F] or –CH₂-Phenyl-OH [Y].

5

3. The peptide of claim 1 or 2, wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.

10 4. A pharmaceutical composition comprising a peptide according to any one of claims 1 to 3.

5. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition comprises a further therapeutic compound.

15 6. The pharmaceutical composition of claim 5, wherein the further therapeutic compound is an apoptosis promoting compound.

7. Use of a peptide of any one of claims 1 to 3, in the manufacture of a medicament for treating or preventing cancer in a patient.